Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma

被引:18
|
作者
Feng, Youfan [1 ]
Zhang, Yuxia [2 ]
Wei, Xiaofang [1 ]
Zhang, Qike [1 ]
机构
[1] Gansu Prov Hosp, Dept Hematol, 204 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
[2] Huining Cty Peoples Hosp, Dept Hematol, Baiyin, Gansu, Peoples R China
关键词
DKK1; human multiple myeloma; pathogenesis; prognosis; BONE-DISEASE; SERUM CONCENTRATIONS; EXPRESSION; CELLS;
D O I
10.3233/CBM-181909
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE: Human multiple myeloma (MM) is a kind of common tumor in middle-aged and elderly people, in which the osteolytic lesion is formed mainly through inhibiting osteoblast (OB) differentiation and promoting osteoclast (OC) differentiation. Dickkopf-1 (DKK1) is a soluble Wnt inhibitor, which has an important correlation with the pathogenesis of human MM. Therefore, the correlations of DKK1 with pathogenesis and prognosis of human MM were investigated in this study. METHODS: The DKK1 expression in tissues and serum of myeloma patients was detected via immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). Correlation between DKK1 expression and survival time of patients was analyzed via Kaplan-Meier analysis. To further study the mechanism of DKK1 expression in pathogenesis and prognosis of human MM, MMcells were treated with DKK1 neutralizing antibody (BHQ880) or transfected with DKK1-small-interfering ribonucleic acid (siRNA) to study its effects on OB differentiation, osteocalcin level, beta-catenin and interleukin-6 (IL-6) secretion. Moreover, the effect of DKK1-siRNA transfection on the activity of U266 cells was detected via methyl thiazolyl tetrazolium (MTT) assay. RESULTS: The DKK1 expression in tissues and serum of myeloma patients was significantly higher than that in control group (p < 0.01). In terms of survival time, the median survival time (45 months) in patients with low DKK1 expression was significantly longer than that in patients with high DKK1 expression (only 22 months). The DKK1 neutralizing antibody (BHQ880) and DKK1-siRNA significantly reduced the DKK1 level in MM cells, promoted the OB differentiation, increased the osteocalcin deposition, promoted the beta-catenin expression and decreased the IL-6 expression and beta-catenin phosphorylation. DKK1-siRNA could also reduce the proliferative activity of MM cells. CONCLUSION: DKK1 is closely related to the pathogenesis and prognosis of human MM, which might be a potential biomarker for the diagnosis of MM.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 50 条
  • [11] DKK1 as a novel target for myeloma immunotherapy
    Qian, Jianfei
    Yi, Qing
    ONCOIMMUNOLOGY, 2012, 1 (05) : 756 - 758
  • [12] On the molecular mechanism of DKK1 inhibition of osteoblast differentiation in multiple myeloma.
    Qiang, Ya-Wei
    Chen, Yu
    Stephens, Owen
    Rubin, Jeff
    Rudikoff, Stuart
    Barlogie, Bart
    Shaughnessy, John D., Jr.
    BLOOD, 2006, 108 (11) : 979A - 979A
  • [13] Epigenetic silencing of the WNT antagonist dickkopf-1(DKK1) in multiple myeloma
    Kocemba, K. A.
    Groen, R. W.
    Kersten, M. J.
    Bloem, A. C.
    Lokhorst, H. M.
    Spaargaren, M.
    Pals, S. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 117 - 117
  • [14] Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma
    Xu, Yinyin
    Chen, Bingda
    George, Suraj K.
    Liu, Beizhong
    RNA BIOLOGY, 2015, 12 (12) : 1314 - 1322
  • [15] Myeloma and Osteolytic Bone Disease: Is DKK1 All It Takes?
    Chen, Bangzheng
    Wu, Hong
    Zeng, Yuxin
    Freeman, John E., III
    Herman, Damir
    Shaughnessy, John D., Jr.
    Barlogie, Bart
    Epstein, Joshua
    BLOOD, 2008, 112 (11) : 598 - 599
  • [16] Serum DKK1 is correlated with γ peak of serum electrophoresis in multiple myeloma: a multicenter biomarker study
    Hashemi, Zahra Sadat
    Khalil, Saeed
    Malaei, Fatemeh
    Mard-Soltani, Maysam
    Jafarisani, Moslem
    Lotfi, Jabar
    Deemeh, Mohammad Reza
    Zakeri, Alireza
    Rasaee, Mohamad Javad
    BIOMARKERS IN MEDICINE, 2019, 13 (15) : 1297 - 1306
  • [17] Dkk1 blocks Wnt-induced osteoprotegerin production in osteoblast progenitors in multiple myeloma
    Qiang, Y.
    Chen, Y.
    Brown, N.
    Rudikoff, S.
    Barlogie, B.
    Shaughnessy, J. D., Jr.
    BONE, 2007, 40 (06) : S144 - S144
  • [18] Active Vaccination with DKK1 Induces Protective and Therapeutic Antitumor Immunity In Multiple Myeloma.
    Qian, Jianfei
    Hong, Sungyoul
    Qin, Hong
    Wang, Ji
    Wei, Jinsong
    Zhang, Liang
    Li, Haiyan
    Zheng, Yuhuan
    Lan, Yongshen
    Yang, Jing
    Lu, Yong
    Kwak, Larry W.
    Yi, Qing
    BLOOD, 2010, 116 (21) : 1253 - 1253
  • [19] The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
    Tian, E
    Zhan, FH
    Walker, R
    Rasmussen, E
    Ma, YP
    Barlogie, B
    Shaughnessy, JD
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26): : 2483 - 2494
  • [20] A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy
    Lu, Chenyang
    Meng, Shan
    Jin, Yanxia
    Zhang, Wanggang
    Li, Zongfang
    Wang, Fang
    Wang-Johanning, Feng
    Wei, Yongchang
    Liu, Hailing
    Tu, Honglei
    Su, Dan
    He, Aili
    Cao, Xingmei
    Zhou, Fuling
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (03) : 413 - 426